GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zhejiang Starry Pharmaceutical Co 603520.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

8.05

-1.59%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Zhejiang Starry Pharmaceutical Co

Its shares trade on Shanghai under the ticker 603520.SS. It has been listed since 9 March 2016. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.45bn and net income of CN¥10.2m. At that date it held total assets of CN¥6.16bn and shareholders' equity of CN¥2.56bn.

Zhejiang Starry Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of active ingredient and intermediate X-CT non-ionic contrast agent and fluoroquinolones series. The company is headquartered in Taizhou, Zhejiang. The company went IPO on 2016-03-09. The X-ray contrast medium's major product is iohexol active pharmaceutical ingredient. Quinolone antimicrobial agents' major products are levofloxacin hydrochloride active pharmaceutical ingredient and levofloxacin hemihydrates active pharmaceutical ingredient.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
9 Mar 2016
Employees
1,842

Leadership

Pay as last reported

  • Mr. Jian HuChairman of the Board, since 2022CN¥1.2m
  • Mr. Weiyi ShenVice Chairman of the Board, General Manager, since 2021CN¥547,500
  • Mr. Junfeng GuoFinance Director, Secretary of the Board
  • Mr. Chaoyang YaoDeputy General Manager
  • Mr. Chun YeDeputy General Manager
  • Mr. Jinsheng HuDirector, since 2004CN¥1.3m
  • Mr. Gang XuDirector
  • Mr. Jiming HuIndependent Director
  • Ms. Meiying MaoIndependent Director
  • Mr. Xiaoke ZhangIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Zhejiang Starry Pharmaceutical employs 1,842 full-time employees in Taizhou, China.
  • The company specializes in X-CT non-ionic contrast agents like iohexol active ingredient.
  • Levofloxacin hydrochloride and hemihydrate are key fluoroquinolones products.

Weaknesses

  • The company's focus on X-ray contrast media limits product diversity in Pharmaceuticals.
  • Zhejiang Starry's reliance on fluoroquinolones may increase market vulnerability.
  • IPO listing in 2016 shows limited recent market expansion.

Opportunities

  • Expanding into new markets for X-CT contrast agents could boost growth.
  • Increasing demand for levofloxacin products in global health care sectors.
  • New opportunities in pharmaceutical research and development for active ingredients.

Threats

  • Competition from other Chinese pharmaceutical companies in contrast agents.
  • Regulatory changes affecting fluoroquinolones in global markets.
  • Potential supply chain disruptions for active pharmaceutical ingredients.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.